BCRX BioCryst Pharmaceuticals, Inc.

0  0%
Previous Close 6.62
Open 6.67
Price To book 315.24
Market Cap 488.84M
Shares 73,955,000
Volume 510,124
Short Ratio 3.60
Av. Daily Volume 1,728,740

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released February 2016 - primary endpoint not met
BCX4161 - OPuS-2
Hereditary angioedema
Phase 2 interim data released February 27, 2017.
BCX7353 - APeX-1
Reduce or eliminate attacks in HAE patients
Approved Dec 22 2014
Peramivir - Study 303

Latest News

  1. After announcing a $45M public offering, BioCryst to launch new trial
  2. BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks
  3. BioCryst to receive royalties from cancer treatment approved in Japan
  4. Stocks of companies with Raleigh-Durham area HQ make a comeback in March
  5. BioCryst Announces Mundipharma Receives Approval for Mundesine® in Japan
  6. BioCryst to Present at the 16th Annual Needham Healthcare Conference
  7. Wait for the Pullback on BioCryst Pharmaceuticals
  8. Don't Let Offerings Blindside Your Thesis
  9. BioCryst Pharmaceuticals (BCRX) Shares March Higher, Can It Continue?
  10. It’s time to vaccinate your investments against a deadly bird flu
  11. BioCryst Pharmaceuticals Prices Public Offering of Common Stock
  12. Biotech Premarket Movers: Spectrum, BioCryst, Curis
  13. The Reason Behind BioCryst Pharmaceuticals, Inc.'s 12% Pop Higher
  14. BioCryst Pharmaceuticals Commences Public Offering of Common Stock
  15. Adamis (ADMP) Shows Strength: Stock Gains 6.7% in Session
  16. BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
  17. Biotech's Outlook Strengthens After President Trump's Speech: Today's Reports on Sarepta Therapeutics and BioCryst Pharmaceuticals
  18. BioCryst 4Q Net 6 Cents a Share Beats Street